A plethora of recent studies have confirmed that SIRT1 indeed inhibited the NF-κB signaling, and the activation of SIRT1 could alleviate a multitude of NF-κB-driven inflammatory and metabolic disorders [10,11]. The gene discussed is NFKB1; the disease is metabolic disease.